Tumor growth in vivo selects for resistance to tumor necrosis factor.
The relationship between in vivo tumor growth and resistance to TNF in WEHI-164 cells has been examined. When a highly TNF-sensitive clone of WEHI-164 was grown in vivo in syngeneic mice it became resistant to rTNF such that a 4 to 5 log higher concentration of TNF was required to produce tumor lysis in vitro. When compared with an in vitro selected TNF-resistant variant, the in vivo selected line was significantly more tumorigenic. The resistant phenotype of both the in vivo and in vitro selected variants was stable in culture and both selected lines were also resistant to lysis by syngeneic spleen cells with natural cytotoxic activity. The parental clone and the two variants were equally sensitive to lysis by allo-CTL and expressed similar levels of MHC class I Ag. Resistance to TNF in the two variants was not a function of de novo production of TNF measured as supernatant TNF activity or TNF mRNA expression. These studies are the first to demonstrate that in vivo tumor growth results in resistance to TNF and therefore may have direct relevance to the efficacy of TNF in the treatment of human neoplasms.
Lattime
E C
EC
Immunology Program, Memorial Sloan-Kettering Cancer Center, New York 10021.
Stutman
O
O
D000818:Animals; D002455:Cell Division / Q000276:immunology; D002460:Cell Line; D002999:Clone Cells / Q000276:immunology / Q000473:pathology; D005260:Female; D005354:Fibrosarcoma / Q000276:immunology / Q000473:pathology*; D015395:Histocompatibility Antigens Class I / Q000032:analysis; D007113:Immunity, Innate; D007694:Killer Cells, Natural / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D010641:Phenotype; D012513:Sarcoma, Experimental / Q000276:immunology / Q000473:pathology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis / Q000276:immunology*
D015395:Histocompatibility Antigens Class I; D014409:Tumor Necrosis Factor-alpha